Keywords: tavocept, falls, short, ph, iii, neuropathy, trials
Tavocept falls short in Ph III neuropathy trials
Article | 07 August 2006
Japanese drugmaker Takeda and the USA's BioNumerik Pharmaceuticals say that the chemo-protective agent Tavocept (dimesna) has fallen short of the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
